SPERO THERAPEUTICS INC. - COMMON STOCK

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

14 نوفمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

07 نوفمبر 2024 16:05:01 بحسب Nasdaq GlobeNewswire

Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update

29 أكتوبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

16 أكتوبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

02 أكتوبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Spero Therapeutics to Present at Upcoming September Investor Conferences

04 سبتمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

05 أغسطس 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

29 يوليو 2024 16:05:16 بحسب Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 يوليو 2024 13:05:00 بحسب Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 يونيو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

16 مايو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

15 مايو 2024 16:05:37 بحسب Nasdaq GlobeNewswire

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

08 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 مايو 2024 16:07:35 بحسب Nasdaq GlobeNewswire

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

13 مارس 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

06 مارس 2024 08:05:00 بحسب Nasdaq GlobeNewswire

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

28 فبراير 2024 08:05:00 بحسب Nasdaq GlobeNewswire

Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference

26 فبراير 2024 08:05:00 بحسب Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 يناير 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Spero Therapeutics Provides Corporate Update and 2024 Outlook

05 يناير 2024 08:05:00 بحسب Nasdaq GlobeNewswire